Clinical Trial Update: Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 [Phase 4]

View source ↗

Summary

This document provides a Phase 4 trial update from Vanderbilt on why ARB/NEP inhibition can cause hypotension in heart failure patients, focusing on Aim 2. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Entresto (sacubitril/valsartan)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Heart Failure | Phase 4 | Status: COMPLETED